Business Context and Reporting Period
Coya Therapeutics, Inc. (COYA) is a clinical-stage biotechnology company focused on developing therapies to enhance the function of regulatory T cells (Tregs) for the treatment of neurodegenerative, autoimmune, and metabolic diseases. The company operates as a single segment and is classified as an emerging growth company and a smaller reporting company.
Reporting Period: Fiscal year ended December 31, 2025.
Key Pipeline Assets:
- COYA 302: A combination biologic (low-dose IL-2 and CTLA4-Ig) currently in a Phase 2 trial (ALSTARS) for Amyotrophic Lateral Sclerosis (ALS). An Investigational New Drug (IND) application for Frontotemporal Dementia (FTD) was accepted by the FDA in January 2026.
- COYA 303: A combination of low-dose IL-2 and a GLP-1 receptor agonist for inflammatory diseases, currently in preclinical stages.
- COYA 201/206: Treg-derived exosome candidates in preclinical development.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Collaboration Revenue | $7.9 | $3.6 |
| Net Loss | $(21.2) | $(14.9) |
| Research & Development Expenses | $16.7 | $11.9 |
| General & Administrative Expenses | $11.4 | $8.9 |
| In-Process R&D Expenses | $2.3 | $0.0 |
| Cash and Cash Equivalents (Year-End) | $46.8 | $38.3 |
| Accumulated Deficit | $(62.0) | $(40.7) |
Liquidity: As of December 31, 2025, the company held $46.8 million in cash. Management estimates that existing cash, combined with $11.1 million in gross proceeds from a January 2026 private placement, will fund operations into the second half of 2027.
Material Changes vs. Prior Period
- Revenue Growth: Collaboration revenue increased by $4.4 million (124%) to $7.9 million. This was driven primarily by $6.7 million in license revenue recognized upon achieving the ALS IND Milestone and the Dosing Milestone under the Dr. Reddy's Laboratories agreement.
- Expense Increases:
- R&D Expenses: Increased by $4.9 million (41%) to $16.7 million, primarily due to clinical advancement of COYA 302 in ALS and increased internal costs.
- In-Process R&D: Increased by $2.3 million due to milestone payments incurred under license agreements (Dr. Reddy's, ARScience, and Houston Methodist) triggered by regulatory milestones.
- G&A Expenses: Increased by $2.6 million (29%) due to higher payroll, professional fees, and investor relations costs.
- Net Loss: Widened by $6.3 million to $21.2 million, reflecting the acceleration of clinical development and milestone-related expenses.
Guidance, Outlook, and Risks
Outlook and Milestones:
- ALS Trial: The ALSTARS Phase 2 trial for COYA 302 in ALS commenced dosing in December 2025. Enrollment is anticipated to complete in the second half of 2026.
- FTD Development: The FDA accepted the IND for COYA 302 for FTD in January 2026. The company plans to advance this into a clinical trial.
- Financing: In January 2026, the company completed a private placement raising $11.1 million gross proceeds, with $10 million provided by Dr. Reddy's Laboratories to accelerate tech transfer and manufacturing scale-up.
Risks and Contingencies:
- Going Concern: The company has incurred significant losses since inception and expects to continue doing so. It will require substantial additional capital to fund operations and clinical trials beyond the second half of 2027.
- Regulatory Risk: Success depends on obtaining regulatory approval for product candidates, which is uncertain. Clinical trials may fail or be delayed.
- Collaboration Dependency: Revenue is currently derived solely from the Dr. Reddy's agreement. Future revenue depends on the success of this collaboration and potential future partnerships.
- Manufacturing: The company relies on third-party manufacturers for clinical and commercial supplies, introducing supply chain risks.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the management's projection that current cash plus the January 2026 proceeds will sustain operations into the second half of 2027.
- Dr. Reddy's Agreement: Review the terms of the Development and License Agreement, specifically the milestone triggers, royalty rates (low to mid-teens), and the $6.0 million royalty waiver agreed upon in the First Amendment.
- Clinical Trial Progress: Monitor enrollment rates and interim data from the ALSTARS Phase 2 trial for ALS, as well as the initiation timeline for the FTD trial.
- License Milestone Obligations: Confirm the status of accrued milestone payments owed to licensors (Houston Methodist, ARScience, Dr. Reddy's) triggered by recent IND acceptances and dosing milestones.
- Capital Requirements: Assess the company's ability to raise additional capital in the future, given the high burn rate and lack of product revenue.